Allograft coronary artery disease (CAD) remains the leading cause of morbidity and mortality affecting the long-term survival of patients after cardiac transplantation. Because there is increasing evidence that imbalances in hemostatic and fibrinolytic pathways are associated with graft failure, we hypothesized that atherothrombotic risk factors may contribute to allograft CAD. This study sought to determine if plasma hemostatic and fibrinolytic parameters are associated with the severity of allograft CAD. The extent of allograft CAD was investigated by angiography and intravascular ultrasound (IVUS) in 16 cardiac transplant recipients. Intimal thickening was quantified using IVUS by measuring the intimal index (Ii =intimal area/!intimal area + luminal area)) in two to five segments of the left anterior descending (LAD) coronary artery. The maximal Ii per patient was calculated and index to the time post-transplant (MxlilYr). Plasma fibrinogen (fGN), tissue-type plasminogen activator (t-PA). plasminogen activator inhibitor-1 (PAI-1), lipoprotein(a) (Lp(a»), and net fibrinolytic activity of plasma were assayed 6-24 months after transplant as indicators of the fibrinolytic system and then correlated with the IVUS measurements. The fGN level correlated with the severity of initimal thickening, MxlilVr (r =0.41, p= 0.008), and was inversely correlated with angiographic tertiary vessel filling (r = -0.25, P = 0.051). In patients with lower plasma fibrinolytic activity (lytic zone less than 100 mm 2 ) , MxlilYr was increased eightfold (0.218± 0.137 versus 0.025 ± 0.021, P= 0.001). t-PA (r =0.0004, P = 0.94), PAI-1 (r = 0.008, p =0.75) and Lp(a) levels (f =0.11, P = 0.21) did not predict MxlilYr. Thus, we demonstrate that plasma FGN and net fibrinolytic activity correlate with the degree of intimal thickening measured by IVUS after cardiac transplantation. These data suggest that fibrin deposition may playa role in allograft CAD after cardiac transplantation.
Introduction
Allograft coronary artery disease (CAD) (i.e., transplant arteriopathy) remains the leading cause of morbidity and mortality affecting tile long-term survival of patients after cardiac transplantation.':" Allograft CAD is a diffuse process, characterized pathologically by concentric intimal thickening of large and medium-sized coronary arteries and veins." Thus, angiographic detection of transplant CAD is difficult and depends largely on the development of pruning of the distal coronary vasculature. Using this technique, coronary atherosclerosis can be demonstrated in up to 50% of patients by 5 years after transplant.':" Intravascular ultrasound (IVUS) is a more sensitive technique, revealing at least mild intimal thickening in the vast majority of patients greater than I year after transplant." Anderson and colleagues have shown that the angiographically silent intimal thickening detected by IVUS typically occurs in the first 3 years after transplantation and progresses over time.".
While numerous clinical and serum factors have been Departments of "Medicine, Cardiovascular Division and "Pathology. Brigham and Women's Hospital. Boston. MA. and <Department of Medicine. Cardiovascular Division. Stanford University Medical Center. Stanford. CA. USA implicated, including cytomegalovirus infection," hypercholesterolemia/ immunosuppressive therapy, If) and histocompatibility mismatch, J I the pathogenesis of allograft CAD remains incompletely defined. I:! A widely held view is that the chronic immune response of the host to the donor vasculature leads to increased adhesion molecule expression, monocyte and T-Iymphocyte infiltration, and cytokine production culminating in smooth muscle cell proliferation, migration, and extracellular matrix deposition.P'!" Immune-mediated vascular injury is further exacerbated by immunosuppressive drug-induced hypertension and hypercholesterolemia. Additional insights into the pathobiology of allograft CAD may be gleaned from recent studies establishing a link between the hemostatic/fibrinolytic system and coronary artery disease, defining several 'atherothrombotic' risk factors for coronary artery disease: elevated levels of fibrinogen (FGN), tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor-I (PAl-I), and lipoproteinra) (Lptal), Epidemiological studies, such as the Northwick Park Heart Study!" and the recently completed European Concerted Action on Thrombosis and Disabilities (ECAT) Angina Pectoris Study, 16 have demonstrated an increased risk of sudden death and nonfatal cardiovascular events in patients with high levels of FGN, [15] [16] [17] factor VII, 15 von Willebrand factor antigen." and t-PA antigen." In patients with coronary atherosclerosis, extent of disease is independently correlated with plasma FGN levcl. 18 2fl Elev-ated levels of t-PA and PAl-I are associated with myocardial infarction 2 1 • 22 and carotid atherosclerosis." Elevated levels of Lpra), a unique lipoprotein comprised of LDL covalently linked to the plasminogen-like apoprotein apoia)." are associated with coronary. cerebral and peripheral atherosclerotic disease (reviewed by Loscalzo"), The association of FON. t-PA. PAI-l and Lpta) with preclinical atherosclerosis suggests that local fibrin deposition may be a critical early event in atherogenesis. Emerging evidence suggests that there may also be a link between the hemostatic/fibrinolytic system and allograft CAD. Lpia) has recently been shown to be a risk factor for the development of angiographically-visible. focal stenoses in cardiac transplant recipients." Depletion of t-PA antigen in vascular smooth muscle cells has been found to be associated with allograft failure. 27.1g In the present study. we sought to define the relationship of hemostatic and fibrinolytic parameters with the extent of post-transplant coronary atherosclerosis quantified by IVUS. Plasma and IVUS measurements were performed in a cohort of clinically stable patients on stable doses of immunosuppression who had not had any recent episodes of rejection.
Methods

Patient population
The study population consisted of patients who had routine. annual surveillance coronary angiography (years 1 through 8) spanning 28 consecutive months at the Brigham and Women's Hospital. Sixty-eight patients out of a total of 183 were studied with intracoronary ultrasound. Exclusion criteria included the presence of peripheral vascular disease. known history of a focal stenosis >509C in the left anterior descending coronary artery. and failure to give informed consent. Within this cohort. blood samples were taken from 16 patients who presented for follow-up catheterization and/or endomyocardial biopsy. The average time between ultrasound evaluation and blood sample collection was 8 ±9 months. The patients excluded from the study had similar clinical and angiographic characteristics compared with the patients studied. None of the patients had acute medical illnesses or rejection noted on their biopsies during the 3-month period prior to or at the time of blood sample collection. All patients included in the study had to be on stable doses of immunosuppressive medications during the previous 3 months. The pathological analysis was done on autopsy specimens from a patient whose cause of death was allograft CAD.
Study protocol
Patients gave written informed consent prior to the catheterization procedure in accordance with the guidelines established by the Committee for the Protection of Human Subjects. The patients were eligible for the study if the left anterior descending (LAD) coronary artery contained no stenosis >509(: on diagnostic catheterization. were obtained at 4 ± I positions of the artery at least I Col apart as the catheter was pulled back through the LAD towards its origin. The time-gain control and reject level were adjusted to obtain optimal images. The positions of the ultrasound catheter were recorded by cineangiography after the injection of contrast. After image acquisition. the catheter was readvanced to the most distal position. and then the catheter was manually pulled back by the operator. examining the whole length of the artery.
Analysis
IVUS measurements
IVUS images were recorded on S-VHS tape and digitized into a Macintosh computer for quantitative analysis (University of California. San Francisco; Intravascular Ultrasound Research Group Software). The ultrasound images at each position were interpreted as previously described" by two observers blinded to the angiographic and plasma measurements who had access to the S-VHS recording as well as the digitized image. The lumen/intima interface was traced by planirnetry, and if measurable intimal thickening was present, the outer border of the thickening was also planimetered. An index of intimal thickness was calculated as (intimal areaj/tlumen + intimal area). Because the ultrasound studies were performed at different times after transplant in this cross-sectional study and Anderson and colleagues have shown that the intimal thickening seen by IVUS typically occurs in the first 3 years after transplantation and progresses over time," the intimal index was adjusted for post-transplant year «intimal indexj/tyears post-transplant) = Ii/Yr). The results of three digitized frames at each position were averaged to obtain data for that position. Datu from the segment with the most disease, thus the maximal intimal index (Mxli/Yr), was used in the subsequent statistical analyses exploring relations with hemostatic/fibrinolytic parameters.
Coronary arteriography
The angiographic findings were independently reviewed by two angiographers blinded to the IVUS and plasma measurements. and a consensus on interpretation was reached. A modified version of the criteria developed by Gao and colleagues' was used to distinguish between discrete coronary lesions (type A) and the more diffuse disease (type B) characteristic of transplant atherosclerosis. Type A lesions are discrete or tubular stenoses less than 10 mm in length involving the proximal. mid or distal coronary segment branches. Type B lesions are diffuse (concentric or irregular) mid or distal segment luminal narrowings beginning either abruptly or as gradual transitions (tapering) from the more normal proximal segments of the arteries. Attenuation of tertiary branch tilling is defined a type C lesion. The amount of tertiary branch filling seen during the late phase of the injection was graded from 1-4+, with 4+ being normal.
Plasma measurements
Blood samples were collected through 7-9 Fr sheaths placed either in the right internal jugular vein (in patients who presented for routine biopsy) or in the right femoral vein (during routine follow-up catheterization). Samples were collected in 0.109 M trisodium citrate and centrifuged to obtain plasma, which was immediately stored at -80°C. Samples were assayed for t-PA antigen and PAI-I antigen via enzyme-linked immunoabsorbent assay (ELISA) using commercially available kits (American Bioproducts Company, Parsippany, NJ, USA). Lp(a) was similarly measured using Macra-Lp(a) (Terumo, Fredericksburg, MD, USA). A quantitative determination of plasma fibrinogen was done according to the method of Claus 30 using an automated coagulometer (ST-4, Diagnostica Stago, American Bioproducts Company, Parsipanny, NJ, USA).
Fibrin plate assay
Plasma fibrinolyte activity was measured using the fibrin plate method as described by Astrup 
Histopathology
Representative myocardial and left anterior descending coronary artery tissue sections from a patient who died secondary to transplant-associated coronary artery disease, were fixed in 10% neutral-buffered formalin. Tissue sections were dehydrated and embedded in paraffin; blocks were sectioned at 5-6 urn thickness and stained routinely with hematoxylin and eosin (H and E), as well as with fibrin'" and Movat pentacbrome" stains. The latter technique differentially stains various elements of the extracellular matrix including collagen, elastin, fibrin and mucopolysaccharides.
Results
Clinical characteristics
The mean age of the study patients was 53 ± 9 years (range 41 to 66 years) ( Table I) . Patients were studied at a mean of 2 ± 2 years (range I to 7 years) after transplantation. The pretransplantation diagnosis was cardiomyopathy in nine patients and coronary artery disease in seven. After transplantation, 13 patients had hypertension requiring treatment and nine were on lipid-lowering therapy for hypercholesterolemia.
Coronary arteriography and IVUS
Eight patients had angiographically detectable type B lesions (diffuse disease of the mid and distal epicardial arteries) characteristic of transplant atherosclerosis, five of these patients having severe type B lesions. Thirteen patients had type C lesions (decreased tertiary branch filling). Only one patient had a discrete stenosis less than 10 mm in length (type A lesion), and this did not involve the left anterior descending coronary artery (the artery studied with IVUS).
Fourteen of the 16 patients had intimal thickening consistent with transplant atherosclerosis on IVUS. The mean intimal index adjusted for transplant year in the segment of LAD with the most disease (MxliNr) was 0.14±0.14 (range 0.00 to 0.51). Figure 2 shows the degree of IVUS-detected intimal thickening index (Mxli/Yr) as a function of plasma FGN level (n = 16). Linear regression analysis identified plasma FGN as significantly associated with Mxli/Yr (r =0.4 I, P = 0.008). Analysis of I-PA (r = 0.0004, p = 0.94), PAI-l (r = 0.008, p = 0.75) and Lp(a) levels (r = 0.11, p = 0.21) revealed no correlation with MxIilYr. 
Relationship between extent of atherosclerosis and hemostatic/fibrinolytic parameters
Statistics
All data is presented as the mean ± the standard error of the mean (SEM). The relationship btween atherothrombotic risk factors and both the continuous IVUS and ordinal angiographic parameters were explored using linear regression. Student's r-tests were used to compare the difference in means of IVUS and angiographic results between the two groups of patients divided by thir plasma fibrinolytic activity. 
Fibrin deposition in post-transplant atherosclerosis
Because we hypothesized that fibrinogen and fibrin deposition may playa role in the pathogenesis of allograft CAD. we analyzed myocardial and coronary artery tissue sections from a patient who died due to severe, diffuse allograft CAD. Extensive focally organizing fibrin deposition adjacent to the intimal hyperplastic lesion of the left anterior descending coronary artery vessel wall is demonstrated (Figure 4 ). Similar fibrin deposition was seen in four out of eight patients who died secondary to severe graft atherosclerosis. Fibrin deposition was not seen in autopsy specimens from cardiac transplant patients whose deaths were secondary to causes other than graft atherosclerosis. Discussion >100mm 2 <100mm 2 Net Plasma LyticActivityby Fibrin Plate Figure 3 Plot of maximal intimal index in the LAD on intravascular ultrasound adjusted for the number of years after transplant (MxlilVr) in patients with plasma fibrinolytic activity <100 mm 2 on fibrin plate assay and those with plasma fibrinolytic activity >100 rnm", Mxli/Yr was eightfold higher (0.218±0.137 versus 0.025 ± 0.021, p=0.001) in patients with fibrinolytic activity < 100 mm 2 than in those with plasma fibrinolytic activity >100 rnrn" (p= 0.001) .
This study demonstrates a significant correlation between the plasma FGN level and coronary intimal thickening in patients with cardiac allografts as quantified by IVUS and a weaker association with angiographic tertiary vessel filling. Net plasma fibrinolytic activity is inversely associated with the extent of allograft CAD. However. no correlation between antigenic measurements of plasma t-PA. PAl-I. or Lpia) and extent of transplant arteriopathy was discerned. 
Atherothrombotic risk factors and their relationship to transplant atherosclerosis
Plasma fibrinolytic activity analysis
Antigenic measurements of fibrinolytic proteins may not adequately reflect their activity because serine proteases such as t-PA and urokinase may be complexed to their natural inhibitors (i.e.. PAl-I). Furthermore. plasmin-independent proteases (e.g. elastase;" cathepsin G;'6 cathepsin 0 32 ) may contribute significant fibrinolytic activity. We therefore measured net plasma fibrinolytic activity using the fibrin plate assay. Figure 3 shows the MxIi/Yr of the 16 patients separated into two groups based on the extent of fibrinolysis: a group with a zone of lysis greater than 100 mrn? (n =6) and another with a lytic zone less than 100 mnr' (n =10). Under these assay conditions. a lytic zone of 100 mnr' is equivalent to that produced by approximately 100 pM t-PA. reported to be within the physiologic plasma concentration range of t-PA. 22 MxIi/Yr was eightfold higher (0.218 ± 0.137 versus 0.025 ± 0.021. p = 0.00 I) in patients with fibrinolytic activity < 100 mm-than in those with plasma fibrinolytic activity > 100 mrrr' tor VII,15.1'! and Lp(a)26 as 'atherothrombotic risk factors' for the development of native coronary artery disease . However. there are limited data correlating these plasma mark ers with allograft CAD. Compared with age-matched controls. heart transplant recip ients have diminished fibrinolytic activity and increased levels of FGN . factor VIIC . and von Willebrand factor antigen." Heart transplant recip ients also have markedl y increased ADP-induced platelet aggregation." a marker for acute coronary events in these patients..w Utilizing endomyocardial biopsy tissue, Labarrere and colleagues 2 7.!M have demonstrated that depletion of t-PA in vascular smooth muscle cell s is associated with graft failure. postulated to be secondary to deficient local fibrinolysis. Our study demonstrates an association between the extent of intimal thickening and plasma FGN level and increased intimal thickening in patients with decreased plasma fibrinolytic activity. No correlation between antigenic measurements of plasma t-PA, PAl-lor Lpta) and extent of transplant atherosclerosis was discerned. Lpta) has previously been found to be a risk factor for the development of focal stenoses in post-transplant patients." In contrast, our study did not find a significant relationship Vascular Medicine 1997; 2: 306-312 between Lp ta ) and the degree of intimal thickening or diffuse luminal narrowing that accompanies accelerated, posttran splant atherosclerosi s. Thi s discrepancy may be secondary to the fact that we excluded patients with angiographic focal stenoses greater than 50 % for safety reason s in performing IVUS and in an effort to pre vent confounding by donor coronary artery disease that may have been present in the heart prior to tran spl antation.
Fibrinogen: 'marker' versus pathophysiologic role
The question of wheth er abnormalities in the hemo static/fibrinolytic system playa key pathophysiologic role in allograft CAD remains unan swered. FGN is a hepatic acute-phase reactanr'" and its elevation may be interpreted as a nonspecific mark er of the inflammatory/immune response associated with the post-transplant state, chronic rejection, and/or atherosclerotic process. However, six prospec tive epidemiologic studies of healthy subjects have demon strated a direct and independent association between plasma FGN concentration and the risk of future coronary events.1 5. 1 7A I~ol Meta-analysis of these six studies showed that FGN was associated with subseq uent myocardial infarction or stroke with an odd s ratio (upper versus lower tert iles of FGN level s) of 2.3 and that there is a uniform co ntinuous increase in risk from the lowest to the highe st level." Moreover. Thompson et all" have shown that FGN is an independent predictor of cor onary e vents in patient s with angina pectoris when C -reacti ve protein. another acute-pha se reactant. was included in the mult ivari ate model. suggesting that the association of FGN with coronary events cannot be solel y explained as a marker of the inflammatory state. Indeed, PAl-I and Lpru). which are also acute-pha se reactants.":" did not correlate with intimal thickening in our study.
Histologic and experimental evidence suggests thar fibrin( ogen) and its breakdown products (FDPs) may directly contribute to atherogenesis via multiple mechanisms. Numerous pathologic studies have demonstrated that fibrin( ogen) and FDPs are located throughout the atheromatous lesion prior to the acute activation of the atherosclerotic plaque:" and colocalize with atherogenic lipoprotein s LDL~y and Lp(a). 50 Vascular wall level s of total fibrinfogen) antigen and LDL are significantly correlated and there is evidence for both continuous formation of cro ss-linked fibrin and fibrinolysis within atherosclerotic lesion s. both processes generating breakdown products that may have atherogenic properties.:' Languino and colleagues have demonstrated that FGN play s a critical role in mediating cell-cell adhe sion events. 52 The endothelial cell adhe sion molecular intercellular adhe sion mole cule-I (lCAM -I ) binds FGN which, in turn. binds the integrin Mac-Ion neutrophils and monocytes. By serving as a 'bridging' molecule. FGN may promote leukocyte adhe sion to the endothelium. a crucial event in the 'response to injury' hypothesis of athero sclerosi s.>' Fibrin(ogen) and FOPs may themselves directly promote the atherosclerotic process by increasing endothelial cell permeability." stimulating proliferation of vascular smooth muscle cells." and by attenuating the release of endothelium-derived relaxing factor'" and prostacyclin." two endothelial products that inhibit platelet adhesion/aggregation and promote vessel dilation . FGN is also a major determinant of blood visco sity, which, if increased. is correlated with the extent of native coronary artery disease." Elevated FGN levels are also associated with enhanced ex vivo platelet aggregation'" and elevated markers of thrombin activation (prothrombin fragment 1.2 and D-dimer levelsj,"" both independent predictors of coronary artery disease." Finally, a direct link between FGN, vessel injury, and subsequent atherosclerosis is supported by data showing that lowering of the plasma fibrinogen level with ancrod (80lJr reduction in plasma FGN) resulted in a significant reduction in neointimal thickening in a rat carotid artery model.?"
Study limitations
This is a cross-sectional study investigating the correlation of atherosclerosis with a hemostatic/fibrinolytic system in a small number of patients (n = 16) at single points in time after transplantation, with time delays between the ultrasound evaluations and blood sampling. Uncontrolled factors, such as immunosuppressive therapy. rejection episodes. and conventional cardiovascular risk factors (hypercholesterolemia, hypertension, diabetes mellitus). exacerbated by the post-transplant state. may themselves modify hemostatic/fibrinolytic parameters. Despite this limitation in study design, FGN and net plasma fibrinolytic activity were found to be predictors of the extent of intimal thickening. A longitudinal study assessing changes in the hemostaric/tibrinolyric system after transplantation with simultaneous IVUS and blood collections obtained serially over time would help clarify these issues.
The IVUS analysis was performed in the proximal twothirds of the left anterior descending coronary artery. It is not certain whether using the position within this part of the coronary tree with the most intimal thickening is an accurate representation of the total disease burden in the coronary tree. Indeed, a recent analysis by Clausell and colleagues?' suggests that IVUS assessment of epicardial intimal thickening may not necessarily correlate with \'ascular changes in intramyocardial arteries visualized in routine endomyocardial biopsy specimens.
Conclusion
In conclusion, the plasma FGN level and net fibrinolytic activity correlate with the severity of intimal thickening after cardial transplantation. While these hemostatic/fibrinolytic parameters may serve as markers of the inflammatory and immune response associated with the post-transplant state, these datu suggest that fibrin deposition may play a pathophysiologic role in allograft CAD after cardiac transplantation. Given the development of new antiplatelet (e.g. oral glycoprotein IIb/IIIa inhibitors). antithrombin (e.g. low molecular weight heparin and hirudin) and FGN-lowering (some fibrate derivatives) agents, the role of fibrin deposition in transplant atherosclerosis and its impact on graft failure warrants further investigation.
